[go: up one dir, main page]

WO2004020609A3 - Streptococcus pneumoniae antigens for diagnosis, treatment and prevention of active infection - Google Patents

Streptococcus pneumoniae antigens for diagnosis, treatment and prevention of active infection Download PDF

Info

Publication number
WO2004020609A3
WO2004020609A3 PCT/US2003/027401 US0327401W WO2004020609A3 WO 2004020609 A3 WO2004020609 A3 WO 2004020609A3 US 0327401 W US0327401 W US 0327401W WO 2004020609 A3 WO2004020609 A3 WO 2004020609A3
Authority
WO
WIPO (PCT)
Prior art keywords
pneumoniae
polypeptides
relates
methods
diagnosis
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/US2003/027401
Other languages
French (fr)
Other versions
WO2004020609A2 (en
WO2004020609A9 (en
Inventor
Andrew Camilli
David L Hava
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Tufts University
Original Assignee
Tufts University
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Tufts University filed Critical Tufts University
Priority to AU2003268353A priority Critical patent/AU2003268353A1/en
Publication of WO2004020609A2 publication Critical patent/WO2004020609A2/en
Publication of WO2004020609A9 publication Critical patent/WO2004020609A9/en
Publication of WO2004020609A3 publication Critical patent/WO2004020609A3/en
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • C07K14/315—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Streptococcus (G), e.g. Enterococci
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)

Abstract

The present invention relates to recombinant antigenic S. pneumoniae polypeptides and fragments thereof. The invention also relates to methods for using these polypeptides to produce immunological responses and to confer immunological protection to disease caused by members of the genus Streptococcus, at least isolates of the S. pneumoniae genus. The invention further relates to nucleic acid sequences which encode antigenic S. pneumoniae polypeptides and to methods for detecting S. pneumoniae nucleic acids and polypeptides in biological samples. The invention also relates to S. pneumoniae-specific antibodies and methods for detecting such antibodies produced in a host animal.
PCT/US2003/027401 2002-08-30 2003-09-02 Streptococcus pneumoniae antigens for diagnosis, treatment and prevention of active infection Ceased WO2004020609A2 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
AU2003268353A AU2003268353A1 (en) 2002-08-30 2003-09-02 Streptococcus pneumoniae antigens for diagnosis, treatment and prevention of active infection

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US40708202P 2002-08-30 2002-08-30
US60/407,082 2002-08-30

Publications (3)

Publication Number Publication Date
WO2004020609A2 WO2004020609A2 (en) 2004-03-11
WO2004020609A9 WO2004020609A9 (en) 2004-05-13
WO2004020609A3 true WO2004020609A3 (en) 2004-07-15

Family

ID=31978415

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2003/027401 Ceased WO2004020609A2 (en) 2002-08-30 2003-09-02 Streptococcus pneumoniae antigens for diagnosis, treatment and prevention of active infection

Country Status (2)

Country Link
AU (1) AU2003268353A1 (en)
WO (1) WO2004020609A2 (en)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BRPI0407384A (en) 2003-02-14 2006-02-21 Pfizer Prod Inc pyridines-triazoles as anti-inflammatory compounds
WO2006048757A2 (en) * 2004-11-05 2006-05-11 Pharmacia & Upjohn Company Llc Anti-bacterial vaccine compositions
WO2006048753A2 (en) * 2004-11-05 2006-05-11 Pharmacia & Upjohn Company Llc Anti-bacterial vaccine compositions
WO2008039838A2 (en) 2006-09-27 2008-04-03 St. Jude Children's Research Hospital Synthetic streptococcus pneumoniae vaccine
GB0714963D0 (en) * 2007-08-01 2007-09-12 Novartis Ag Compositions comprising antigens
BRPI0907010A2 (en) 2008-02-01 2015-07-07 Sanofi Pasteur Ltd Analysis for the diagnosis of streptococcus pneumoniae
NZ597858A (en) 2009-06-29 2014-01-31 Genocea Biosciences Inc Vaccines and compositions against streptococcus pneumoniae
CN103501808A (en) 2010-12-03 2014-01-08 赛诺菲巴斯德有限公司 Composition for immunization against streptococcus pneumoniae
CN103501809B (en) 2011-01-20 2018-08-10 健诺西生物科学公司 Vaccines and compositions against Streptococcus pneumoniae
CN104321335A (en) * 2012-02-24 2015-01-28 诺华股份有限公司 Pilus proteins and compositions
JP2019503201A (en) * 2015-11-25 2019-02-07 ウェイク フォーレスト ユニバーシティ ヘルス サイエンシーズWake Forest University Health Sciences Pneumococcal inhibitor composition and method of use thereof
US11013793B2 (en) * 2018-09-12 2021-05-25 Affinivax, Inc. Multivalent pneumococcal vaccines

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6420135B1 (en) * 1996-10-31 2002-07-16 Human Genome Sciences, Inc. Streptococcus pneumoniae polynucleotides and sequences

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6420135B1 (en) * 1996-10-31 2002-07-16 Human Genome Sciences, Inc. Streptococcus pneumoniae polynucleotides and sequences

Also Published As

Publication number Publication date
AU2003268353A1 (en) 2004-03-19
WO2004020609A2 (en) 2004-03-11
AU2003268353A8 (en) 2004-03-19
WO2004020609A9 (en) 2004-05-13

Similar Documents

Publication Publication Date Title
O’Brien-Simpson et al. An immune response directed to proteinase and adhesin functional epitopes protects against Porphyromonas gingivalis-induced periodontal bone loss
Liu et al. Immunological characterizations of the nucleocapsid protein based SARS vaccine candidates
AU2001276619A1 (en) Immunisation against chlamydia pneumoniae
DK0942983T3 (en) Streptococcus pneumoniae antigens and vaccines
US9795664B2 (en) Vaccine against streptococcal infections based on recombinant proteins
WO2000039299A3 (en) Streptococcus antigens
HK1043943A1 (en) Streptococcus pneumoniae proteins and vaccines
WO1999042588A3 (en) Group b streptococcus antigens
AU5328299A (en) Uses of the borreliacidal epitope(s) of borrelia burgdorferi outer surface protein c (ospc) as vaccine
WO2004020609A3 (en) Streptococcus pneumoniae antigens for diagnosis, treatment and prevention of active infection
US8795690B2 (en) Protective proteins of S. agalactiae, combinations thereof and methods of using the same
De et al. Purification and characterization of Streptococcus pneumoniae palmitoylated pneumococcal surface adhesin A expressed in Escherichia coli
Pinitkiatisakul et al. Immunisation of mice against neosporosis with recombinant NcSRS2 iscoms
WO2001081380A3 (en) Immunogenic pneumococcal protein and vaccine compositions thereof
EP0826774A3 (en) Staphylococcal Fab I enoyl-ACP reductase
Wang et al. Evaluation of a tandem Chlamydia psittaci Pgp3 multiepitope peptide vaccine against a pulmonary chlamydial challenge in mice
WO2001046225A3 (en) Chlamydia antigens and corresponding dna fragments and uses thereof
EP0834568A3 (en) Novel saliva binding protein
WO2007005627A3 (en) Tuberculosis antigen detection assays and vaccines
ATE366583T1 (en) IDENTIFICATION OF SPECIFIC DIFFERENTIALLY EXPRESSED ANTIGENS FROM MYCOBACTERIUM AND MEDICAL USE OF THE MYCOBACTERIUM PROTEINS RV0068 AND RV3407
EP1219635A3 (en) Chlamydia pneumoniae antigenes
KR20010020529A (en) Compounds encoding the protective m-like protein of streptococcus equi and assays therefor
WO2003013601A1 (en) Toxin associated with sudden infant death syndrome, and uses thereof

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NI NO NZ OM PG PH PL PT RO RU SC SD SE SG SK SL SY TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IT LU MC NL PT RO SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
COP Corrected version of pamphlet

Free format text: PAGES 1/9-9/9, DRAWINGS, REPLACED BY NEW PAGES 1/11-11/11; DUE TO LATE TRANSMITTAL BY THE RECEIVINGOFFICE

122 Ep: pct application non-entry in european phase
NENP Non-entry into the national phase

Ref country code: JP

WWW Wipo information: withdrawn in national office

Country of ref document: JP